Timothy R Rebbeck

List of Publications by Year
in descending order

166 papers	14,772 citations	31949 53 h-index	20343 116 g-index
174 all docs	174 docs citations	174 times ranked	17601 citing authors

#	Article	IF	Citations
1	Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations. New England Journal of Medicine, 2002, 346, 1616-1622.	13.9	1,565
2	Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality. JAMA - Journal of the American Medical Association, 2010, 304, 967.	3.8	1,241
3	Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2009, 101, 80-87.	3.0	786
4	Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program. Journal of the National Cancer Institute, 2002, 94, 1365-1372.	3.0	611
5	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell, 2015, 28, 529-540.	7.7	601
6	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
7	Akt-Dependent Metabolic Reprogramming Regulates Tumor Cell Histone Acetylation. Cell Metabolism, 2014, 20, 306-319.	7.2	473
8	Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. Journal of Clinical Oncology, 2005, 23, 7804-7810.	0.8	396
9	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
10	Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncology, The, 2006, 7, 223-229.	5.1	333
11	Early detection of cancer. Science, 2022, 375, eaay9040.	6.0	291
12	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
13	Challenges and opportunities in cancer control in Africa: a perspective from the African Organisation for Research and Training in Cancer. Lancet Oncology, The, 2013, 14, e142-e151.	5.1	223
14	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
15	RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
16	Improvement of pathology in sub-Saharan Africa. Lancet Oncology, The, 2013, 14, e152-e157.	5.1	201
17	Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. Seminars in Radiation Oncology, 2017, 27, 3-10.	1.0	201
18	Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nature Genetics, 2011, 43, 570-573.	9.4	198

#	Article	IF	Citations
19	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations. JAMA Oncology, 2016, 2, 1434.	3.4	189
20	Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genetics, 1996, 12, 309-311.	9.4	183
21	Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent. Prostate Cancer, 2013, 2013, 1-12.	0.4	180
22	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	5.8	178
23	Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2014, 106, dju091.	3.0	176
24	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
25	Assessing the function of genetic variants in candidate gene association studies. Nature Reviews Genetics, 2004, 5, 589-597.	7.7	169
26	Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell, 2018, 34, 549-560.e9.	7.7	168
27	Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. JAMA - Journal of the American Medical Association, 2019, 321, 704.	3.8	168
28	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	0.8	155
29	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
30	Estimates of Cancer Incidence in Ethiopia in 2015 Using Population-Based Registry Data. Journal of Global Oncology, 2018, 4, 1-11.	0.5	150
31	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. Journal of Clinical Oncology, 2016, 34, 91-101.	0.8	146
32	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 2789-2796.	0.8	127
33	Prophylactic Surgery in Women With a Hereditary Predisposition to Breast and Ovarian Cancer. Journal of Clinical Oncology, 2000, 18, 1980-1995.	0.8	124
34	Precancer Atlas to Drive Precision Prevention Trials. Cancer Research, 2017, 77, 1510-1541.	0.4	116
35	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. International Journal of Radiation Oncology Biology Physics, 2014, 89, 709-713.	0.4	99
36	Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncology, The, 2022, 23, e251-e312.	5.1	94

#	Article	IF	Citations
37	Cancer Risks Associated With *BRCA1* and *BRCA2* Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	0.8	90
38	BAG-1: A Novel Biomarker Predicting Long-Term Survival in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2001, 19, 992-1000.	0.8	89
39	Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 23-32.	1.1	88
40	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
41	Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis, 2008, 30, 269-274.	1.3	87
42	Racial Differences in Genomic Profiling of Prostate Cancer. New England Journal of Medicine, 2020, 383, 1083-1085.	13.9	87
43	Oncologic Care and Pathology Resources in Africa: Survey and Recommendations. Journal of Clinical Oncology, 2016, 34, 20-26.	0.8	80
44	A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. International Journal of Cancer, 2007, 120, 1523-1528.	2.3	79
45	Dissecting racial disparities in multiple myeloma. Blood Cancer Journal, 2020, 10, 19.	2.8	79
46	Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. PLoS Genetics, 2020, 16, e1008641.	1.5	78
47	Estrogen Sulfation Genes, Hormone Replacement Therapy, and Endometrial Cancer Risk. Journal of the National Cancer Institute, 2006, 98, 1311-1320.	3.0	76
48	Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030387.	2.9	76
49	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer, 2020, 126, 717-724.	2.0	64
50	Generalizability of established prostate cancer risk variants in men of African ancestry. International Journal of Cancer, 2015, 136, 1210-1217.	2.3	62
51	Precision Prevention and Early Detection of Cancer: Fundamental Principles. Cancer Discovery, 2018, 8, 803-811.	7.7	62
52	Inherited genetic predisposition in breast cancer. , 1999, 86, 2493-2501.		60
53	Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10750-10758.	3.3	57
54	Hereditary neuralgic amyotrophy: evidence for genetic homogeneity and mapping to chromosome 17q25. Human Genetics, 1997, 101, 277-283.	1.8	56

#	Article	IF	Citations
55	Prophylactic oophorectomy in women at increased cancer risk. Current Opinion in Obstetrics and Gynecology, 2007, 19, 27-30.	0.9	54
56	Genetic Hitchhiking and Population Bottlenecks Contribute to Prostate Cancer Disparities in Men of African Descent. Cancer Research, 2018, 78, 2432-2443.	0.4	52
57	Modification of <i>BRCA1</i>-Associated Breast and Ovarian Cancer Risk by <i>BRCA1</i>-Interacting Genes. Cancer Research, 2011, 71, 5792-5805.	0.4	49
58	Characterization of the Cancer Spectrum in Men With Germline<i>BRCA1</i>and<i>BRCA2</i>Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
59	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clinical Cancer Research, 2021, 27, 320-329.	3.2	46
60	Genetics, Epidemiology, and Cancer Disparities: Is it Black and White?. Journal of Clinical Oncology, 2006, 24, 2164-2169.	0.8	45
61	Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. Journal of the National Cancer Institute, 2021, 113, 719-726.	3.0	45
62	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
63	Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. British Journal of Cancer, 2018, 118, 1013-1019.	2.9	42
64	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. New England Journal of Medicine, 2019, 380, 2070-2072.	13.9	42
65	Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis. JNCI Cancer Spectrum, 2020, 4, pkaa029.	1.4	41
66	Ethnicity, Ancestry, and Race in Molecular Epidemiologic Research. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2467-2471.	1.1	40
67	Risk factors for endometrial cancer in black and white women: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). Cancer Causes and Control, 2015, 26, 287-296.	0.8	40
68	Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. European Urology, 2019, 75, 1038-1040.	0.9	38
69	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clinical Cancer Research, 2019, 25, 4290-4299.	3.2	38
70	Temporal trends and racial disparities in global prostate cancer prevalence. Canadian Journal of Urology, 2014, 21, 7496-506.	0.0	37
71	AACR White Paper: Shaping the Future of Cancer Prevention â€" A Roadmap for Advancing Science and Public Health. Cancer Prevention Research, 2018, 11, 735-778.	0.7	36
72	African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 70.e15-70.e22.	0.8	35

#	ARTICLE	IF	CITATIONS
73	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	2.3	35
74	Precision Prevention of Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2713-2715.	1.1	34
75	The spectrum of <i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in Middle Eastern, North African, and South European countries. Human Mutation, 2019, 40, e1-e23.	1.1	34
76	Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015. JAMA Network Open, 2019, 2, e193759.	2.8	34
77	P gene as an inherited biomarker of human eye color. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 782-4.	1.1	34
78	Modification of Ovarian Cancer Risk by <i>BRCA1/2</i>-Interacting Genes in a Multicenter Cohort of <i>BRCA1/2</i> Mutation Carriers. Cancer Research, 2009, 69, 5801-5810.	0.4	31
79	Effect of hormone metabolism genotypes on steroid hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition. Menopause, 2010, 17, 1026-1034.	0.8	31
80	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i>/<i>2</i> Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
81	Impact of neighborhood socioeconomic status, income segregation, and greenness on blood biomarkers of inflammation. Environment International, 2022, 162, 107164.	4.8	29
82	Pairwise Combinations of Estrogen Metabolism Genotypes in Postmenopausal Breast Cancer Etiology. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 444-450.	1.1	28
83	Peritoneal carcinomatosis after riskâ€reducing surgery in <i>BRCA1/2</i> mutation carriers. Cancer, 2018, 124, 952-959.	2.0	27
84	Cancer in sub-Saharan Africa. Science, 2020, 367, 27-28.	6.0	27
85	Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Medical and Pediatric Oncology, 2000, 35, 526-530.	1.0	26
86	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
87	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	1.1	26
88	A Custom Genotyping Array Reveals Population-Level Heterogeneity for the Genetic Risks of Prostate Cancer and Other Cancers in Africa. Cancer Research, 2020, 80, 2956-2966.	0.4	25
89	Cancer Progress and Priorities: Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 267-277.	1.1	25
90	A practical approach to adjusting for population stratification in genome-wide association studies: principal components and propensity scores (PCAPS). Statistical Applications in Genetics and Molecular Biology, 2018, 17, .	0.2	24

#	ARTICLE	IF	CITATIONS
91	Individual and joint effects of metformin and statins on mortality among patients with high‑risk prostate cancer. Cancer Medicine, 2020, 9, 2379-2389.	1.3	24
92	RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. Journal of the National Cancer Institute, 2015, 107, .	3.0	23
93	Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. Cancer Cell, 2021, 39, 1042-1044.	7.7	23
94	Inherited Variation at MC1R and Histological Characteristics of Primary Melanoma. PLoS ONE, 2015, 10, e0119920.	1.1	22
95	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
96	Neighborhood greenness and burden of non-communicable diseases in Sub-Saharan Africa: A multi-country cross-sectional study. Environmental Research, 2021, 196, 110397.	3.7	22
97	A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. European Urology, 2022, 81, 458-462.	0.9	22
98	Bilateral Risk-Reducing Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 177-182.	2.3	21
99	The contribution of residential greenness to mortality among men with prostate cancer: a registry-based cohort study of Black and White men. Environmental Epidemiology, 2020, 4, e087.	1.4	20
100	Joint effects of inflammation and androgen metabolism on prostate cancer severity. International Journal of Cancer, 2008, 123, 1385-1389.	2.3	19
101	GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer. Human Molecular Genetics, 2016, 25, ddw092.	1.4	19
102	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
103	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
104	Somatic mutations in <i>CDH1</i> and <i>CTNNB1</i> in primary carcinomas at 13 anatomic sites. Oncotarget, 2017, 8, 85680-85691.	0.8	16
105	Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 268.	1.7	16
106	The distinct impacts of race and genetic ancestry on health. Nature Medicine, 2022, 28, 890-893.	15.2	16
107	Conservative management of low‑risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer, 2019, 125, 3338-3346.	2.0	15
108	Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. ELife, 0, 11, .	2.8	15

#	Article	IF	Citations
109	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. European Urology Oncology, 2019, 2, 405-412.	2.6	14
110	A Framework for Promoting Diversity, Equity, and Inclusion in Genetics and Genomics Research. JAMA Health Forum, 2022, 3, e220603.	1.0	13
111	Lack of Effect Modification between Estrogen Metabolism Genotypes and Combined Hormone Replacement Therapy in Postmenopausal Breast Cancer Risk: Table 1.. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1318-1320.	1.1	12
112	No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Research and Treatment, 2009, 115, 185-192.	1.1	12
113	Context-Dependent Effects of Genome-Wide Association Study Genotypes and Macroenvironment on Time to Biochemical (Prostate Specific Antigen) Failure after Prostatectomy. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2115-2123.	1.1	12
114	Exome-Wide Association Study of Endometrial Cancer in a Multiethnic Population. PLoS ONE, 2014, 9, e97045.	1.1	12
115	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
116	Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. Cancer, 2021, 127, 2714-2723.	2.0	12
117	Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate. Journal of Global Oncology, 2018, 4, 1-14.	0.5	11
118	Prostate Cancer Screening, Diagnostic, Treatment Procedures and Costs in Sub-Saharan Africa: A Situational Analysis. Cancer Control, 2022, 29, 107327482210849.	0.7	11
119	African-American Race Is a Predictor of Seminal Vesicle Invasion After Radical Prostatectomy. Clinical Genitourinary Cancer, 2015, 13, e65-e72.	0.9	10
120	Patient Characteristics and Outcomes of Nonmetastatic Breast Cancer in Haiti: Results from a Retrospective Cohort. Oncologist, 2020, 25, e1372-e1381.	1.9	10
121	Variability in loss of constitutional heterozygosity across loci and among individuals: Association with candidate genes in ductal breast carcinoma. , 1996, 17, 117-125.		9
122	What stresses men? predictors of perceived stress in a population-based multi-ethnic cross sectional cohort. BMC Public Health, 2013, 13, 113.	1.2	9
123	Gene–environment interactions between JAZF1 and occupational and household lead exposure in prostate cancer among African American men. Cancer Causes and Control, 2014, 25, 869-879.	0.8	9
124	Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 570-577.	1.1	9
125	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer, 2020, 126, 1407-1412.	2.0	8
126	The contribution of inherited genotype to breast cancer. Breast Cancer Research, 2002, 4, 85-9.	2.2	7

#	Article	IF	Citations
127	Strengthening care and research for women's cancers in Sub-Saharan Africa. Gynecologic Oncology Reports, 2017, 21, 109-113.	0.3	7
128	Rethinking Environmental Carcinogenesis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1870-1875.	1.1	7
129	Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1139-1145.	1.1	7
130	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. European Urology Open Science, 2022, 40, 19-26.	0.2	7
131	Risk prediction with linked markers: Pedigree analysis. American Journal of Medical Genetics Part A, 1995, 59, 24-32.	2.4	6
132	Defining Priorities for Reducing Disparities in Cancer Mortality. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 570-572.	1.1	6
133	The rising burden of cancer in low– and middle–Human Development Index countries. Cancer, 2021, 127, 2864-2866.	2.0	6
134	Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi–phased study of prostate cancer. Cancer Communications, 2021, 41, 1387-1397.	3.7	6
135	Discovering novel driver mutations from pan-cancer analysis of mutational and gene expression profiles. PLoS ONE, 2020, 15, e0242780.	1.1	6
136	Racial Disparities in Prostate Cancer: Evaluation of Diet, Lifestyle, Family History, and Screening Patterns. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 982-990.	1.1	6
137	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate, 2021, 81, 683-693.	1.2	5
138	Inherited genotype and prostate cancer outcomes. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 945-52.	1.1	5
139	DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. JNCI Cancer Spectrum, 2022, 6, pkab097.	1.4	5
140	The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes and Control, 2018, 29, 685-697.	0.8	4
141	Body Mass Index, Chemotherapy-Related Weight Changes, and Disease-Free Survival in Haitian Women With Nonmetastatic Breast Cancer. JCO Global Oncology, 2020, 6, 1656-1665.	0.8	4
142	Toward Equitable Access to Tertiary Cancer Care in Rwanda: A Geospatial Analysis. JCO Global Oncology, 2022, , .	0.8	4
143	The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer. Npj Precision Oncology, 2022, 6, .	2.3	4
144	Epidemiological Approaches to the Identification of Cancer Predisposition Genes. , 2003, 222, 309-325.		3

#	ARTICLE	IF	CITATIONS
145	Editorial: The Fruits of the Genomic Revolution. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 362-362.	1.1	3
146	Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations. Gynecologic Oncology, 2020, 156, 363-376.	0.6	3
147	Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position. Cancer, 2021, 127, 2525-2534.	2.0	3
148	High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study. Blood, 2021, 138, 152-152.	0.6	3
149	Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer â€" A propensity score analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 547-552.	2.0	3
150	Reply to V. Fallet et al. Journal of Clinical Oncology, 2022, 40, 2509-2510.	0.8	3
151	Building a Funded Research Program in Cancer Health Disparities: Considerations for Young Investigators. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 882-885.	1.1	2
152	Abstract 67: Quantifying Transportation Barriers in Rwandan Patients Seeking Treatment for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 67-67.	1.1	2
153	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68.	0.2	2
154	Raceâ€specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990â€"2017. Cancer Medicine, 0, , .	1.3	2
155	Academic Bigotry. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1445-1446.	1.1	1
156	Molecular Pharmacoepidemiology. , 0, , 571-586.		1
157	Prostate cancer outcomes for African American and caucasian patients undergoing radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, 40-40.	0.8	1
158	Regular Aspirin Use and Mortality in Multiple Myeloma Patients. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.EPI-21-0946-E.2021.	1.1	1
159	Biomarkers of inherited susceptibility and cancer. Iarc (international Agency for Research on Cancer) Scientific Publications, 2004, , 91-103.	0.4	1
160	Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospital systems serving health disparity populations.. Journal of Clinical Oncology, 2022, 40, 6555-6555.	0.8	1
161	Response to Boucher *et al*.. International Journal of Cancer, 2008, 123, 2467-2468.	2.3	0
162	EZH2 expression and clinical outcome in African-American men with prostate cancer.. Journal of Clinical Oncology, 2017, 35, 81-81.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Predictors of post-surgical race-specific prostate cancer progression.. Journal of Clinical Oncology, 2017, 35, 5048-5048.	0.8	0
164	Retrospective analysis to describe trends in first-ever prostate-specific antigen (PSA) testing for primary healthcare facilities in the Gauteng Province, South Africa, between 2006 and 2016. BMJ Open, 2022, 12, e050646.	0.8	0
165	Predictors of overall survival among Black South African men treated with androgen-deprivation therapy for metastatic prostate cancer.. Journal of Clinical Oncology, 2022, 40, 5046-5046.	0.8	0
166	Prevalence of monoclonal gammopathy of undetermined significance in black South African men.. Journal of Clinical Oncology, 2022, 40, e20032-e20032.	0.8	0